PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

Intralesional therapy with oncolytic viruses (OVs) leads to the activation of local and systemic immune pathways, which may present targets for further combinatorial therapies. Here, we used human tumor histocultures as well as syngeneic tumor models treated with Newcastle disease virus (NDV) to ide...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of clinical investigation Vol. 128; no. 4; pp. 1413 - 1428
Main Authors:	Zamarin, Dmitriy, Ricca, Jacob M., Sadekova, Svetlana, Oseledchyk, Anton, Yu, Ying, Blumenschein, Wendy M., Wong, Jerelyn, Gigoux, Mathieu, Merghoub, Taha, Wolchok, Jedd D.
Format:	Journal Article
Language:	English
Published:	United States American Society for Clinical Investigation 01.04.2018
Subjects:	Analysis Apoptosis Biomedical research Cancer therapies Care and treatment Cell death Clinical trials Drug therapy Genes Health aspects Immunotherapy Infections Interferon Ligands Lymphocytes Lymphocytes T Melanoma Metastases Metastasis Newcastle disease Oncolysis Patient outcomes PD-1 protein PD-L1 protein Skin cancer Therapeutic targets Tumors Viruses United States Oncology Immunology Gene therapy T cells Immunotherapy
ISSN:	0021-9738, 1558-8238, 1558-8238
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!